India's Biocon Issues One-For-One Bonus Shares, Says Acquisitions, New Drug Development To Drive Earnings
This article was originally published in PharmAsia News
BANGALORE, India - India's largest biotechnology drug firm Biocon said clinical trials for diabetes, psorasis, arthritis and cancer drugs are progressing and it plans to launch a new cardio-diabetes division to focus on brand building for its statin Statix (atorvastatin)
You may also be interested in...
BANGALORE, India - India's Biocon Ltd. said it paid €30 million ($43.5 million) to buy a 70 percent stake in German drug firm AxiCorp GmbH to expand marketing and distribution of products such as injectable insulin, generics, biosimilars and biologics in Europe
NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases
Abraxis BioScience and Biocon have signed a licensing agreement that gives the Los Angeles firm the right to develop a biosimilar of granulocyte-colony stimulating factor in North America and the European Union, the companies announced July 19